Cargando…

PReS-FINAL-2345: Frequency of radiographic damage and progression in individual joints in children with juvenile idiopathic arthritis

Detalles Bibliográficos
Autores principales:	Giancane, G, Pederzoli, S, Norambuena, X, Ioseliani, M, Sato, J, Gallo, MC, Negro, G, Ruperto, N, Martini, A, Ravelli, A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4044976/ http://dx.doi.org/10.1186/1546-0096-11-S2-P335

Ejemplares similares

PReS-FINAL-2164: Agreement among musculoskeletal pediatric specialists in the assessment of radiographic joint damage in juvenile idiopathic arthritis
por: Pignataro, R, et al.
Publicado: (2013)

PReS-FINAL-2132: Defining criteria for high disease activity in juvenile idiopathic arthritis: definition and validation of juvenile arthritis disease activity score cutoffs
por: Consolaro, A, et al.
Publicado: (2013)

PReS-FINAL-2143: Treat-to-target strategy in juvenile idiopathic arthritis: experience in 175 newly-diagnosed patients
por: Negro, G, et al.
Publicado: (2013)

PReS-FINAL-2134: Assessment of radiographic progression in patients (pts) with systemic juvenile idiopathic arthritis (sjia) treated with tocilizumab (TCZ): 2-year results from the tender trial
por: Malattia, C, et al.
Publicado: (2013)

PReS-FINAL-2089: Temporomandibular joint involvement and quality of life in juvenile idiopathic arthritis
por: Frid, P, et al.
Publicado: (2013)

PReS-FINAL-2001: The impact of adalimumab on growth in patients with juvenile idiopathic arthritis
por: Ruperto, N, et al.
Publicado: (2013)

PReS-FINAL-2011: Preliminary validation of a new hybrid measure of muscle strength for juvenile dermatomyositis
por: Marafon, D, et al.
Publicado: (2013)

Tocilizumab may slow radiographic progression in patients with systemic or polyarticular-course juvenile idiopathic arthritis: post hoc radiographic analysis from two randomized controlled trials
por: Malattia, Clara, et al.
Publicado: (2020)

PReS-FINAL-2010: Predictive value of whole-body MRI in juvenile dermatomyositis
por: Malattia, C, et al.
Publicado: (2013)

PReS-FINAL-2028: ANA positivity and a younger age at onset, but not disease category, predict the risk of uveitis in italian children with juvenile idiopathic arthritis
por: Schiappapietra, B, et al.
Publicado: (2013)

PReS-FINAL-2043: Cardiac involvement in juvenile idiopathic arthritis
por: Rossetto, E, et al.
Publicado: (2013)

PReS-FINAL-2167: What is the potential of intra-articular corticosteroid injections to induce sustained remission in children with juvenile idiopathic arthritis?
por: Lanni, S, et al.
Publicado: (2013)

PReS-FINAL-2344: Radiographic evaluation of joint space width compared to cartilage thickness as assessed by ultrasonography in knees of children with juvenile idiopathic arthritis
por: Pradsgaard, D, et al.
Publicado: (2013)

PReS-FINAL-2165: Pharmacogenetic determinants of response to methotrexate in juvenile idiopathic arthritis
por: Pastore, S, et al.
Publicado: (2013)

PReS-FINAL-2070: Efficacy of biologic treatments in juvenile idiopathic arthritis with a polyarticular course: an indirect comparison
por: Sawyer, L, et al.
Publicado: (2013)

PReS-FINAL-2169: Exposure-response modeling of canakinumab in the avoidance of flares in children with systemic juvenile idiopathic arthritis
por: Xiong, Y, et al.
Publicado: (2013)

PReS-FINAL-2018: The P53 gene polymorphisms and juvenile idiopathic arthritis
por: Kozhevnikov, A, et al.
Publicado: (2013)

PReS-FINAL-2097: Evaluation of gait in children with juvenile idiopathic arthritis
por: Baydogan, SN, et al.
Publicado: (2013)

PReS-FINAL-2147: Immunological consequences of biologicals in juvenile idiopathic arthritis
por: Swart, JF, et al.
Publicado: (2013)

PReS-FINAL-2140: Neutropenia with Tocilizumab (TCZ) treatment is not associated with increased infection risk in patients with systemic juvenile idiopathic arthritis (SJIA)
por: De Benedetti, F, et al.
Publicado: (2013)

PReS13-SPK-1332: Assessment of disease activity and damage in juvenile idiopathic arthritis
por: Ravelli, A
Publicado: (2013)

PReS-FINAL-2098: Evaluation of the disease course of Italian children with juvenile idiopathic arthritis treated with etanercept: preliminary results in 313 patients
por: Verazza, S, et al.
Publicado: (2013)

Evaluation of the power of six clustering features in identifying a homogeneous disease subset in juvenile idiopathic arthritis (JIA)
por: Magnani, A, et al.
Publicado: (2008)

PReS-FINAL-2081: Accelerometer-assessed daily activity in juvenile idiopathic arthritis
por: Noergaard, M, et al.
Publicado: (2013)

PReS-FINAL-2109: Genetic variations in patients with juvenile idiopathic arthritis and uveitis
por: Reinards, TH, et al.
Publicado: (2013)

PReS-FINAL-2048: Treatment with methotrexate plus leflunomide for juvenile idiopathic arthritis
por: Quesada-Masachs, E, et al.
Publicado: (2013)

PReS-FINAL-2007: Adolescent clinic for young patients with juvenile idiopathic arthritis
por: Sørensen, SK
Publicado: (2013)

PReS-FINAL-2060: The role of stress factors in the onset of juvenile idiopathic arthritis
por: Stepanenko, N, et al.
Publicado: (2013)

PReS-FINAL-2176: Declines in levels of disease activity and physical disability in children with juvenile idiopathic arthritis seen in standard clinical care over the last 25 years
por: Consolaro, A, et al.
Publicado: (2013)

PReS-FINAL-2012: Introducing a new approach to clinical care of juvenile dermatomyositis: the juvenile dermatomyositis multidimensional assessment report
por: Varnier, GC, et al.
Publicado: (2013)

PReS-FINAL-2110: Tocilizumab for patients with oligoarticular juvenile idiopathic arthritis refractory to conventional therapy
por: Sato, T, et al.
Publicado: (2013)

PReS-FINAL-2129: Whole-body versus localized magnetic resonance imaging in the assessment of juvenile dermatomyositis
por: Madeo, A, et al.
Publicado: (2013)

Final validation of a new composite disease activity score for juvenile idiopathic arthritis: the Juvenile Arthritis Disease Activity Score (JADAS)
por: Consolaro, A, et al.
Publicado: (2008)

PReS-FINAL-2157: Efficacy of canakinumab in the treatment of systemic juvenile idiopathic arthritis: a 12-week pooled post-hoc analysis
por: Quartier, P, et al.
Publicado: (2013)

PReS-FINAL-2158: Effect of canakinumab on functional ability and health-related quality of life in systemic juvenile idiopathic arthritis (SJIA) patients
por: Quartier, P, et al.
Publicado: (2013)

Impact of involvement of individual joint groups on subdimensions of functional ability scales in juvenile idiopathic arthritis
por: Meiorin, S, et al.
Publicado: (2008)

Juvenile Idiopathic Arthritis: Diagnosis and Treatment
por: Giancane, Gabriella, et al.
Publicado: (2016)

Is it worth including subtalar joint in ultrasound ankle assessment of patients with juvenile idiopathic arthritis?
por: Lanni, Stefano, et al.
Publicado: (2014)

PReS-FINAL-2152: Biomarkers as predictors of early inactive disease in children with juvenile idiopathic arthritis
por: Lavric, M, et al.
Publicado: (2013)

PReS-FINAL-2156: Analysis of gene expression and inflammation biomarkers in systemic juvenile idiopathic arthritis (SJIA) patients on canakinumab therapy
por: Nirmala, N, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ckhund8va2f60mdbvghsbh6con